Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice

Z. Sarang, P. Molnár, Tamás Németh, Szabolcs Gomba, T. Kardon, Gerry Melino, Susanna Cotecchia, L. Fésüs, Z. Szondy

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Tissue transglutaminase (TG2) is a protein cross-linking enzyme known to be expressed by hepatocytes and to be induced during the in vivo hepatic apoptosis program. TG2 is also a G protein that mediates intracellular signaling by the alpha-1b-adrenergic receptor (AR) in liver cells. Fas/Fas ligand interaction plays a crucial role in various liver diseases, and administration of agonistic anti-Fas antibodies to mice causes both disseminated endothelial cell apoptosis and fulminant hepatic failure. Here we report that an intraperitoneal dose of anti-Fas antibodies, which is sublethal for wild-type mice, kills all the TG2 knock-out mice within 20 hours. Although TG2-/- thymocytes exposed to anti-Fas antibodies the at the same rate as wild-type mice, TG2-/- hepatocytes show increased sensitivity toward anti-Fas treatment both in vivo and in vitro, with no change in their cell surface expression of Fas, levels of FLIPL (FLICE-inhibitory protein), or the rate of I-κBα degradation, but a decrease in the Bcl-xL expression. We provide evidence that this is the consequence of the impaired AR signaling that normally regulates the levels of Bcl-xL in the liver. In conclusion, our data suggest the involvement of adrenergic signaling pathways in the hepatic regeneration program, in which Fas ligand-induced hepatocyte proliferation with a simultaneous inhibition of the Fas-death pathway plays a determinant role.

Original languageEnglish
Pages (from-to)578-587
Number of pages10
JournalHepatology
Volume42
Issue number3
DOIs
Publication statusPublished - Sep 2005

Fingerprint

GTP-Binding Proteins
Hepatocytes
Cell Death
Anti-Idiotypic Antibodies
Fas Ligand Protein
Liver
CASP8 and FADD-Like Apoptosis Regulating Protein
Adrenergic alpha-1 Receptors
Apoptosis
Acute Liver Failure
Thymocytes
Knockout Mice
Adrenergic Agents
Adrenergic Receptors
Liver Diseases
Regeneration
Endothelial Cells
transglutaminase 2
Enzymes
Proteins

ASJC Scopus subject areas

  • Hepatology

Cite this

Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice. / Sarang, Z.; Molnár, P.; Németh, Tamás; Gomba, Szabolcs; Kardon, T.; Melino, Gerry; Cotecchia, Susanna; Fésüs, L.; Szondy, Z.

In: Hepatology, Vol. 42, No. 3, 09.2005, p. 578-587.

Research output: Contribution to journalArticle

@article{882bbd0a759c45b1b1a21d4dd228263d,
title = "Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice",
abstract = "Tissue transglutaminase (TG2) is a protein cross-linking enzyme known to be expressed by hepatocytes and to be induced during the in vivo hepatic apoptosis program. TG2 is also a G protein that mediates intracellular signaling by the alpha-1b-adrenergic receptor (AR) in liver cells. Fas/Fas ligand interaction plays a crucial role in various liver diseases, and administration of agonistic anti-Fas antibodies to mice causes both disseminated endothelial cell apoptosis and fulminant hepatic failure. Here we report that an intraperitoneal dose of anti-Fas antibodies, which is sublethal for wild-type mice, kills all the TG2 knock-out mice within 20 hours. Although TG2-/- thymocytes exposed to anti-Fas antibodies the at the same rate as wild-type mice, TG2-/- hepatocytes show increased sensitivity toward anti-Fas treatment both in vivo and in vitro, with no change in their cell surface expression of Fas, levels of FLIPL (FLICE-inhibitory protein), or the rate of I-κBα degradation, but a decrease in the Bcl-xL expression. We provide evidence that this is the consequence of the impaired AR signaling that normally regulates the levels of Bcl-xL in the liver. In conclusion, our data suggest the involvement of adrenergic signaling pathways in the hepatic regeneration program, in which Fas ligand-induced hepatocyte proliferation with a simultaneous inhibition of the Fas-death pathway plays a determinant role.",
author = "Z. Sarang and P. Moln{\'a}r and Tam{\'a}s N{\'e}meth and Szabolcs Gomba and T. Kardon and Gerry Melino and Susanna Cotecchia and L. F{\'e}s{\"u}s and Z. Szondy",
year = "2005",
month = "9",
doi = "10.1002/hep.20812",
language = "English",
volume = "42",
pages = "578--587",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice

AU - Sarang, Z.

AU - Molnár, P.

AU - Németh, Tamás

AU - Gomba, Szabolcs

AU - Kardon, T.

AU - Melino, Gerry

AU - Cotecchia, Susanna

AU - Fésüs, L.

AU - Szondy, Z.

PY - 2005/9

Y1 - 2005/9

N2 - Tissue transglutaminase (TG2) is a protein cross-linking enzyme known to be expressed by hepatocytes and to be induced during the in vivo hepatic apoptosis program. TG2 is also a G protein that mediates intracellular signaling by the alpha-1b-adrenergic receptor (AR) in liver cells. Fas/Fas ligand interaction plays a crucial role in various liver diseases, and administration of agonistic anti-Fas antibodies to mice causes both disseminated endothelial cell apoptosis and fulminant hepatic failure. Here we report that an intraperitoneal dose of anti-Fas antibodies, which is sublethal for wild-type mice, kills all the TG2 knock-out mice within 20 hours. Although TG2-/- thymocytes exposed to anti-Fas antibodies the at the same rate as wild-type mice, TG2-/- hepatocytes show increased sensitivity toward anti-Fas treatment both in vivo and in vitro, with no change in their cell surface expression of Fas, levels of FLIPL (FLICE-inhibitory protein), or the rate of I-κBα degradation, but a decrease in the Bcl-xL expression. We provide evidence that this is the consequence of the impaired AR signaling that normally regulates the levels of Bcl-xL in the liver. In conclusion, our data suggest the involvement of adrenergic signaling pathways in the hepatic regeneration program, in which Fas ligand-induced hepatocyte proliferation with a simultaneous inhibition of the Fas-death pathway plays a determinant role.

AB - Tissue transglutaminase (TG2) is a protein cross-linking enzyme known to be expressed by hepatocytes and to be induced during the in vivo hepatic apoptosis program. TG2 is also a G protein that mediates intracellular signaling by the alpha-1b-adrenergic receptor (AR) in liver cells. Fas/Fas ligand interaction plays a crucial role in various liver diseases, and administration of agonistic anti-Fas antibodies to mice causes both disseminated endothelial cell apoptosis and fulminant hepatic failure. Here we report that an intraperitoneal dose of anti-Fas antibodies, which is sublethal for wild-type mice, kills all the TG2 knock-out mice within 20 hours. Although TG2-/- thymocytes exposed to anti-Fas antibodies the at the same rate as wild-type mice, TG2-/- hepatocytes show increased sensitivity toward anti-Fas treatment both in vivo and in vitro, with no change in their cell surface expression of Fas, levels of FLIPL (FLICE-inhibitory protein), or the rate of I-κBα degradation, but a decrease in the Bcl-xL expression. We provide evidence that this is the consequence of the impaired AR signaling that normally regulates the levels of Bcl-xL in the liver. In conclusion, our data suggest the involvement of adrenergic signaling pathways in the hepatic regeneration program, in which Fas ligand-induced hepatocyte proliferation with a simultaneous inhibition of the Fas-death pathway plays a determinant role.

UR - http://www.scopus.com/inward/record.url?scp=24144442640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144442640&partnerID=8YFLogxK

U2 - 10.1002/hep.20812

DO - 10.1002/hep.20812

M3 - Article

C2 - 16108039

AN - SCOPUS:24144442640

VL - 42

SP - 578

EP - 587

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -